Connect your AI

Azenta AZTA Available for sale investments

Available for sale investments at other companies

Twist Bioscience CorporationTWST

——

BioLife SolutionsBLFS

——

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

Revenue$144.8M+1.0%

Gross profit$62.0M-1.2%

Operating income-$165.8M-811%

Net income-$160.8M-237%

EPS (diluted)-$3.49-236%

Balance sheet

Cash & equivalents$125.2M—

Total debt$55.7M—

Total equity$1.6B-8.3%

Total assets$1.9B—

Cash flow

Operating cash flow$13.5M-6.2%

CapEx$7.4M-0.1%

Free cash flow$6.1M-12.7%

Valuation

Market cap$1.1B-16.3%

Enterprise value$1.03B—

P/S1.8×-0.2×

Profitability

Gross margin40%-1.0pp

Operating margin-31.6%-59.7pp

Net margin-29.1%-80.7pp

FCF margin8.6%—

Returns & leverage

Return on equity-10.7%-22.4pp

Debt / equity0×—

Current ratio2.8×—

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Azenta’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Azenta's available for sale investments?: Azenta (AZTA) reported available for sale investments of $324.32M in Q1 2026.